ROIV Stock Price Today (October 2026) — Roivant Sciences Ltd. Analysis & Key Metrics 2026-10-08
Roivant Sciences Ltd. (ROIV) is trading at $34.21, down 1.55% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $48.08 (40.5% upside).
- Volatility is low (24.23% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-33.50% YoY) alongside competitive pressures in the Biotechnology space.
ROIV Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Roivant Sciences Ltd. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $20.98B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+40.5% upside potential
Key Investor Questions About ROIV
What investors need to know before buying
Based on current market data, ROIV presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 30.14)
- Fundamentals say: Challenging (declining revenue trends)
ROIV's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ROIV investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $107.15M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ROIV stock traded between $15.25 and $42.50 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 24.23% annualized volatility and β=0.94, the stock exhibits moderate correlation to market moves—making ROIV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?
Roivant Sciences Ltd. (NASDAQ:ROIV) shares jumped about 17% after the company reported positive mid-stage results for mosliciguat, its experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The readout gives Roivant (NASDAQ:ROIV) another late-stage pipeline opportunity shortly after the company won U.S. approval for Lisraya, its treatment for adults with dermatomyositis. READ ALSO: […]
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus.
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test
Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that […]
What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?
Roivant Sciences (NasdaqGS: ROIV) reported positive Phase 2 PHocus trial results for mosliciguat in PH-ILD patients. The study showed statistically significant and clinically meaningful changes in pulmonary vascular resistance and six-minute walk distance measures. Management highlighted the PHocus findings at recent scientific conference presentations focused on pulmonary hypertension and interstitial lung disease. There is more to Roivant than the PHocus mosliciguat data investors are...
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story
Roivant Sciences Ltd. (NASDAQ:ROIV) shares surged 18% on September 8 after the biotech company reported strong Phase 2 results for an experimental treatment for pulmonary hypertension. The positive topline results from the Phase 2 PHocus trial of Mosliciguat provide an important clinical validation for one of the company’s most promising pipeline assets. The candidate drug […]
Podcast: key readouts from ESC and ERS
The healthcare team dive into the latest data and emerging trends from the ESC Congress and ERS Congress.
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?
Investors rewarded three very different catalysts spanning artificial intelligence, biotechnology, and energy.
Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41%
Roivant Sciences Ltd. (NASDAQ:ROIV) soared to a new all-time high on Tuesday after reporting stellar results from the clinical trial of its treatment candidate for pulmonary hypertension associated with interstitial lung disease (PH-ILD). In intra-day trading, the stock jumped to its highest price of $42.50 before trimming gains to end the session just up by […]
Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs
Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease treatments.
Explore More Analysis for ROIV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 9, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is currently trading at $34.21. The RSI (14-day) is at 30.1, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $48.08 implies 40.5% upside from current levels. Volatility is moderate at 24.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Roivant Sciences Ltd. (ROIV): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 7.01. Price-to-Sales is 3933.84. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering ROIV, the consensus price target is $48.08. This represents a 40.5% upside from the current price of $34.21. The range spans from a low target of $41.00 to a high target of $55.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Roivant Sciences Ltd. (ROIV) investors include: 1. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 2. Declining revenue (-33.5% YoY), indicating potential business headwinds. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Roivant Sciences Ltd.'s (ROIV) current debt and financial health profile: Total debt stands at $107.15M. The debt-to-equity ratio is 0.02x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 16.72, indicating strong short-term liquidity. The quick ratio is 13.62. The company holds $3.84B in cash and equivalents. Free cash flow is negative at -$1.13B, which could limit the company's ability to manage debt obligations.